TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06069726: A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

Sponsor: Duke University · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06069726 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06069726 Rescue Dossier →